James R. Baker, Jr., MD

Dr. Baker is Chief Executive Officer and founder of the company.  He is the inventor of the platform technology and an internationally recognized expert in immunology and biologic nanotechnology.  Dr. Baker invented the NanoStat technology at the University of Michigan, where he is the Ruth Dow Doan Professor of Medicine and Head of Allergy and Immunology at the Medical School.  He is also the Director of the University of Michigan Nanotechnology Institute, which is focused on the use of nanotechnology in biomedical applications. He is one of three editors of the National Nanotechnology Initiative’s Research Directives, and Chairs the Nanotechnology for Medicine and Biology study section at National Institutes of Health (“NIH”).  Dr. Baker is a board-certified internist, allergist and immunologist.

George Arida

George Arida has a proven track record of identifying emerging healthcare companies and guiding growth, business strategy, and financial decisions to help create exciting exit opportunities. He joined Venture Investors in 2000 and was appointed Managing Director of the General Partner of Venture Investors Early Stage Fund IV in 2006. Prior to joining Venture Investors, Mr. Arida was the CFO of a financial consulting and brokerage firm.

Mr. Arida served as Chairman of the Board of Directors of Nerites, Inc.through the January 2011 acquisition by Kensey Nash and served as Chairman of Zystor Therapeutics, Inc. He currently serves as Chairman of the Board of Directors of Celleration, Inc. He also serves on the Board of Directors for Chromatin, Inc., ProCertus BioPharm, Inc. and the Mid-America Healthcare Investors Network. He serves as a guest lecturer at the University of Chicago Booth School of Business and the University of Wisconsin School of Business.

Arida holds a Bachelor of Science degree in Chemical Engineering from the University of Illinois at Urbana-Champaign and a Master of Business Administration degree with high honors from the University of Chicago.

Ronald M. Cresswell, PhD

Dr. Cresswell is the former Senior Vice President and Chief Scientific Officer of Warner-Lambert, and has served on the Board of Directors of Esperion Therapeutics, Inc., Allergan, Inc., Curagen Corporation, and Vasogen, Inc.  He brings over 30 years of research and commercial development experience in various therapeutic areas to NanoBio.  Dr. Cresswell began his tenure with Warner-Lambert in 1988 as the President of Research and Development of the Parke-Davis Pharmaceutical Research Division.  From 1989-1998, he served as Vice President and Chairman of the Parke-Davis Worldwide Pharmaceutical Research Division.  Dr. Cresswell’s vision and leadership in the development of Lipitor® at Parke-Davis was instrumental in the product's ultimate success.  Dr. Cresswell joined Warner-Lambert from Laporte Industries, Ltd., an international chemical company, where he was Chief Operating Officer.  Prior to this, Dr. Cresswell was with Burroughs Wellcome for over 20 years.  At Burroughs Wellcome, he held a broad range of research and development positions in both the United Kingdom and the United States, and was responsible for a research staff of over 3,000 people.

Daniel B. Dubin, MD

Dr. Dubin currently serves as Vice Chairman and a Director at Leerink Swann, a leading healthcare and biotechnology investment banking firm. A Harvard-trained dermatologist, Dr. Dubin served as Ambulatory Medical Director of the dermatology practice at Brigham and Women’s Hospital. In 1996, Dr. Dubin co-founded MEDACorp to provide life science companies and institutional investors with expert insight into the development and adoption of biopharmaceuticals, medical devices and diagnostics. When MEDACorp merged with Leerink Swann in 2001, Dr. Dubin became a Director at Leerink Swann and later assumed the position of Vice Chairman. Dr. Dubin also serves on the board of Elemé Medical, a cellulite treatment company.

Robert C. Moellering, Jr., MD

Dr. Moellering brings over 30 years of extensive medical experience to the NanoBio Board. He is broadly recognized as a worldwide expert in the areas of infectious diseases and antimicrobial technologies.  Dr. Moellering is the Shields Warren-Mallinckrodt Professor of Medical Research at Harvard Medical School.  From 1998 to 2005, he served as the Herrman Ludwig Blumgart Professor of Medicine at Harvard Medical School and Physician-in-Chief and Chairman of the Department of Medicine at the Beth Israel Deaconess Medical Center.  Dr. Moellering received his M.D. degree cum laude from Harvard Medical School and continued his distinguished career at Massachusetts General Hospital and Harvard Medical School.  He has also served as President and CEO of Harvard Medical Faculty Physicians at Beth Israel Deaconess Medical Center.  Dr. Moellering has been actively involved in research on the mechanisms of action and mechanisms of resistance of antimicrobial agents for the past 25 years.  He has defined some of the important mechanisms of interaction of antimicrobial agents, which have been reported extensively in scientific journals.  He is the Editor-in-Chief Emeritus of Antimicrobial Agents and Chemotherapy, Editor of Infectious Disease Clinics of North America, and Editor of the European Journal of Clinical Microbiology and Infectious Diseases.

David M. Stout

David M. Stout has served as a top-level pharmaceutical executive both nationally and internationally for the past 30 years. His most recent position was President of Pharmaceutical Operations for GlaxoSmithKline Pharmaceuticals.  In this capacity, Mr. Stout led all global commercial activities, global manufacturing and all vaccine-related activities for the company, including research and development.  Additionally, Mr. Stout directed the corporate pandemic flu preparedness program, an international effort that supports governments, health authorities and company employees around the world in responding to a global influenza pandemic.  Prior to his tenure at GSK, Mr. Stout served as President of SmithKline Beecham’s North American pharmaceutical business, launching two major products and two sales force expansions.  Mr. Stout’s pharmaceutical career began at Warner-Lambert Pharmaceutical Company and continued at Schering-Plough Corporation, where he served in numerous positions, including President of Schering Laboratories.

Peter G. Ulrich

Peter Ulrich has more than 35 years of executive experience in biotechnology and healthcare, with more than 20 years of CEO tenure. Mr. Ulrich most recently served as President and CEO of TargeGen, co-founding the company and leading it from inception through exit in a $560 million acquisition by Sanofi-aventis. Prior to co-founding TargeGen, Mr. Ulrich was President and CEO of Avia Technology Partners, a biotechnology-oriented, strategic, consulting firm. Ulrich has held positions with Baxter Health Care, La Jolla Pharmaceutical Company, MedClone, Inc., NeuroVir Therapeutics Inc., LipoGen, Inc., BIOTX, Analytical Luminescence Laboratory, and The University of Alabama at Birmingham and UAB Research Foundation.

Mr. Ulrich's entrepreneurial achievements include a consistent track record of success with early stage life sciences companies, the ability to secure over $150M in private equity financing from venture capital sources and recognition by Ernst & Young as an Entrepreneur of the Year.